UK markets closed

NIKKEI 225
38,855.37
-44.65(-0.11%)
HANG SENG
18,821.16
-6.19(-0.03%)
CRUDE OIL
79.95
+2.23(+2.87%)
GOLD FUTURES
2,353.90
+19.40(+0.83%)
DOW
38,741.18
-328.41(-0.84%)
Bitcoin GBP
52,808.80
-2,078.35(-3.79%)

What's next for state pension? Sunak unveils 'Triple Lock Plus'

The Triple Lock Plus would introduce a new age-related allowance for pensioners

AZN May 2024 64.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.0300

0.0000

(0.00%)

As of 01:59PM EDT. Market open.

Zacks
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Business Wire
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
CAMBRIDGE, England, May 27, 2024--Dato-DXd TL01 OS HLR
Zacks
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.